Mehri Nazeri - Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Houshang Nemati - Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

Recurrent miscarriage affects approximately 1% of all couples trying to conceive and is defined as 3 or more consecutive pregnancy losses before 20 weeks of amenorrhoea. Hypothyroidism is a common disease, with an estimated incidence of 0.3% to 0.5% for overt and 3% for subclinical hypothyroidism (SH) in pregnant women. In 50% of recurrent miscarriages (RM) the cause remains unknown. Cell-free DNA (cfDNA) testing revealed to be valuable as a predictive biomarker in several pathological conditions. There are a growing number of studies considering cell-free DNA (cfDNA) as a surrogate marker for diagnosis, prognosis and monitor of patents response rate to treatment. These findings has gain a significant of interest to developing cfDNA for monitoring of recurrent miscarriage. In this review, we first addressed the recent advancements and highlight the current challenges toward the development of cfDNA as powerfull tool against recurrent miscarriage. Then, we focus on the technical quantitative analysis of cfDNA in clinically healthy females and pregnant women with SH.

subclinical hypothyroidism, SH, recurrent miscarriage, predictive biomarker and cfDNA